reason report
tough quarter think tam unchang execut
stori pt
bottom line morn deliv first meaning sale
miss sinc sale come
us consensu growth repres
slowest growth quarter sinc share open
nearli stock deliv spectacular ralli throughout
day close seem reflect
short-cov well least real buy long-onli
fund look take advantag reason valuat
continu believ monopoli multibillion-
dollar oper margin -- uniqu asset smid-
cap med-tech despit weak quarter somewhat shaken
confid stori -- least near term -- stick
outperform rate believ estimate
 patient -- includ cardiogen shock high-risk
pci -- unchang manag team deserv level
trust faith right ship improv
execut deliv meaning beat prior
quarter noth fundament chang market
beyond rp dear doctor letter seem
gener lower cath lab volum broadli relat
potenti confus caus earli februari dear doctor
letter agre manag final fda letter
resolv put issue/concern bed relat
execut believ ceo minogu earn benefit
doubt base clear success to-dat continu
like stock medium-to-long term also acknowledg
share could rangebound even fade bit
earn late july/earli august today solid recoveri
littl way catalyst next month
boost share meaning instil increas investor
confid march volum weak truli transitori
natur if/when manag return consist beats/rais
beyond -- much lower hurdl clear --
think share appreci multipl re-expand
reiter op pt pt price target vs prior
appli ev/sal multipl estim
assum current multipl hold steadi roll
valuat forward continu believ top-tier
sale growth profil profit warrant premium vs smid-cap
med-tech group averag
estim adjust newli issu guidanc revenue/
ep decreas vs prior line
midpoint compani newli issu revenu oper
margin guidanc rang revenue/ep
compani inform svb leerink llc research
revenu dilut gaap ep
medic suppli devic
ev/sal multipl
net debt total capit
year price history/av daili volume mil
pleas refer page import disclosur price chart analyst certif
rate share outperform price target believ abiom
manufactur impella famili percutan ventricular assist devic pvad well-
posit deliv sustain strong double-digit sale growth near-to-midterm
time-frame project sale compound-annual-growth-rate
compani drive increas penetr prophylact high-risk percutan
coronari intervent pci cardiogen shock patient popul estim nearli
patient treat abiom impella impella cp
pci perform annual base medacorp physician
convers anywher pci could consid high-risk
would benefit impella anoth pci cardiogen shock patient
compani benefit new product higher flow impella cp receiv pma approv
 april indic shock new geographi notabl
japan receiv approv octob launch impella
addit receiv fda approv impella rp right heart failur
compani continu add new center
center total ad center per quarter
us biggest barrier impella adopt awar impella
pma-approv protect pci impella devic includ higher flow impella
cp approv cardiogen shock aggress market train
hospit heart team util broad clinic dataset train capabl impella
six clinic guidelin drive awar help guid clinic
practic eas patient select
even adopt inflect upon protect pci pma approv late believ
impella adopt pois ramp given
highli under-penetrated market opportun within protect pci cardiogen shock
impella today penetr
concert effort among physician rais awar around treat grow
number complex patient pci procedur volum patient grow
mid-single-digit rang base estim
pma approv protect pci cardiogen shock allow
aggress market impella use broad clinic dataset support safeti efficaci
cost-effect well train clinician nurs
indic geograph expans on-going launch impella rp
patient opportun on-going launch japan current
patient balloon pump patient extracorpor membran
oxygen ecmo repres low-hang fruit impella view
oper margin expans stori believ abiom drive on-going posit oper
leverag primarili within sg ultim push oper margin
next month believ share
move higher current level compani continu deliv consist quarterli sale
beat push oper margin higher
price target appli ev/sal multipl estim
assum stabl multipl vs current estim continu believ
top-tier sale growth profil profit warrant premium vs smid-cap
med-tech group averag repres uniqu asset increasingli volatil market
risk rate valuat includ failur drive increas util rate
and/or continu add new account steadi rate failur execut pipelin
launch new geographi potenti reimburs declin potenti competit
pvad product secur approv gain meaning market share potenti
dollar million except per share data
total good sold
research develop expens
consensu incom statement item includ contributor factset
revenu
servic revenu
consensu detail revenu item visibl alpha
consensu
compani report factset consensu visibl alpha consensu svb leerink estim
dollar million except per share data
total good sold
research develop
revenu
consensu incom statement item includ contributor factset
servic revenu
consensu detail revenu item visibl alpha
consensu
compani report factset consensu visibl alpha consensu svb leerink estim
dollar million except per share data
total good sold
research develop
cog sale
sg sale
 sale
oper expens sale
compani report svb leerink estim
abiom sale y/i
share-bas
pivot compar today standard care immedi reperfus without
 fda approv initi trial
patient site
trial take year complet
submiss fda month later
ecp expand cardiac power true cathet target three
liter flow ideal pump high-risk pci physician want
anyth larger way pump short area
inflow valv thin soft membran abras
valv ecp deliv design clinic durat
hour fr pump expand fr
impella btr expect later outer year estim flow l/min
cathet fr pump shorter design durat month year
also wearabl driver allow patient get discharg
hospit impella btr minim invas approach axillari arteri
bridg
still pre-clin test aug
-a februari first-in-man ecp still
expect
 jan first-in-man ecp expect
impella next gener pump smaller profil design
implant axillari arteri wean algorithm implant
axillari arteri allow greater flexibl patient walk around hospit
may improv outcom
jan control eu launch underway
patient alreadi germani
jan first-in-man expect
